Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its Buy rating on the stock.

This increase in valuation came after Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement under which it will acquire Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Enliven Therapeutics, Inc.’s (NASDAQ:ELVN) competitor, through a subsidiary for approximately $6.7 billion.

Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho

Earlier, on March 24, Mizuho also lifted its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $41 to $45 and maintained its Outperform rating on the stock.

The research firm pointed to recent Phase 1b data for ELVN-001 as the key factor for this increase in the price target. Mizuho sees Enliven Therapeutics, Inc. (NASDAQ:ELVN) as an under-rated asset in the chronic myeloid leukemia market. The firm added that it expects more data from ELVN-001’s Phase 1a/b trial in mid-year.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for cancer treatment.

While we acknowledge the risk and potential of ELVN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ELVN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Car Stocks to Buy in 2026 and 10 Best AI Stocks to Buy for the Next 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.